Medical Devices

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Next Generation Sequencing (NGS) Market – Industry Trends and Forecast to 2029

Medical Devices | Published Report | Dec 2021 | MEA | 350 Pages | No of Tables: 32 | No of Figures: 34

Report Description

Middle East and Africa Next Generation Sequencing (NGS) Market, By Product  (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (South Africa and Rest of Middle East And Africa) Industry Trends & Forecast to 2029.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights : Middle East and Africa Next Generation Sequencing (NGS) Market

Middle East and Africa next generation sequencing (NGS) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.7% in the forecast period of 2022 to 2029 and is expected to reach USD 791.18 million by 2029. Increasing research activities next generation sequencing (NGS) act as driver for the next generation sequencing (NGS) market growth.

High-throughput sequencing, most widely regarded as the "next-generation" sequencing (NGS), is now integrated into routine clinical practice due to the numerous technical and functional developments, while early protocols relied on samples harvested outside of typical workflows in clinical pathology, standard formalin-fixed, paraffin-embedded specimens which can be used more regularly as starting material for NGS. In addition, protocols are being amassed for the analysis and interpretation of NGS data, as well as knowledge bases, allowing clinicians to act more easily on genomic information at the patient care point. The presence of wide range of products of the next generation sequencing used in the diagnosis of chronic diseases is satisfying the need of the healthcare facilities. The increased technological advancement leads to development of highly efficient next generation sequencing (NGS) in the market. 

Major factors driving the growth of next generation sequencing (NGS) market are use of next generation sequencing in drug development and wide portfolio offered by major player and the factor which hampers the growth of the next generation sequencing (NGS) market includes high cost of next generation sequencing products and product recall.

The next generation sequencing (NGS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the next generation sequencing (NGS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Next Generation Sequencing (NGS) Market Scope and Market Size

The next generation sequencing (NGS) market is segmented on basis of product, applications, end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the Middle East and Africa next generation sequencing (NGS) market is segmented into instrument, consumables, and services. In 2022, instrument segment is dominating the next generation sequencing (NGS) market as the companies are trying to expand their business to through sales of products in these regions which is acting as the reason for dominance.
  • On the basis of application, the Middle East and Africa next generation sequencing (NGS) market is segmented into diagnostic, drug discovery, biomarker discovery, precision medicine, agriculture and animal research. In 2022, the diagnostic segment is dominating the Middle East and Africa next generation sequencing (NGS) market due to the fact that the prevalence of disease is high in these regions and the use of NGS in diagnosis is low in these countries
  • On the basis of end user, the Middle East and Africa next generation sequencing (NGS) market is segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies. In 2022, research center and academic & government institutes is dominating in the Middle East and Africa next generation sequencing (NGS) market as the research on the companies has collaborated with African institutes which has knowledge of African gene which dominate the segment

Next Generation Sequencing (NGS) Market Country Level Analysis

The next generation sequencing (NGS) market is analyzed and market size information is provided by the country, product, application, and end user as referenced above.

The countries covered in the next generation sequencing (NGS) market report are South Africa and rest of Middle East and Africa.

Diagnostic segment in South Africa of the region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of use of next generation technology in hospitals and clinics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Next generation sequencing (NGS) Treatment, is Boosting the Market Growth of Next generation sequencing (NGS) market.

The next generation sequencing (NGS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Next Generation Sequencing (NGS) Market Share Analysis

Next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to next generation sequencing (NGS) market.

Some of the major companies which are dealing in the next generation sequencing (NGS) are Agilent Technologies, Inc., ThermoFisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., Roche Sequencing (A subsidiary of F. Hoffman La Roche), BGI (A subsidiary of BGI Group), Oxford Nanopore Technologies plc, MACROGEN CO., LTD., DNASTAR, Geneious, Partek, Incorporated, PerkinElmer Inc., Takara Bio Inc., bioMérieux SA, among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the next generation sequencing (NGS) market.

For instance,

  • In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Middle East and Africa market and leading to upsurgecompany’s growth in the coming years.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the next generation sequencing (NGS) market which also provides the benefit for organization’s profit growth.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 PESTEL'S ANALYSIS

3.2 PORTER'S FIVE FORCES MODEL

4 REGULATIONS OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE

5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY

5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER

5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT

5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION

5.2 RESTRAINTS

5.2.1 HIGH COST OF INSTRUMENT

5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS

5.2.3 CYBER SECURITY CONCERN IN GENOMICS

5.3 OPPORTUNITIES

5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

5.3.2 PRODUCT APPROVAL IN RECENT YEARS

5.3.3 ADVANCEMENT IN NGS TECHNOLOGY

5.4 CHALLENGES

5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS

5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB

6 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY

6.1 IMPACT ON PRICE

6.2 IMPACT ON DEMAND

6.3 IMPACT ON SUPPLY CHAIN

6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

6.5 CONCLUSION

7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT

7.1 OVERVIEW

7.2 INSTRUMENTS

7.2.1 HISEQ SERIES

7.2.2 MISEQ SERIES

7.2.3 ION TORRENT

7.2.4 PACBIO RS II

7.2.5 SEQUEL SYSTEM

7.2.6 SOLID

7.2.7 OTHERS

7.3 CONSUMABLE

7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT

7.3.2 SAMPLE PREPARATION CONSUMABLES

7.3.3 OTHERS

7.4 SERVICES

7.4.1 SEQUENCING SERVICES

7.4.2 DATA MANAGEMENT

8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 DIAGNOSTICS

8.3 BIOMARKER DISCOVERY

8.4 PRECISION MEDICINE

8.5 DRUG DISCOVERY

8.6 AGRICULTURE & ANIMAL RESEARCH

9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER

9.1 OVERVIEW

9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES

9.4 HOSPITAL & CLINICS

10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION

10.1 MIDDLE EAST AND AFRICA

10.1.1 SOUTH AFRICA

10.1.2 REST OF MIDDLE EAST AND AFRICA

11 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 COMPANY PROFILING

12.1 ILLUMINA, INC.

12.1.1 COMPANY SNAPSHOT

12.1.2 REVENUE ANALYSIS

12.1.3 COMPANY SHARE ANALYSIS

12.1.4 SWOT ANALYSIS

12.1.5 PRODUCT PORTFOLIO

12.1.6 RECENT DEVELOPMENTS

12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)

12.2.1 COMPANY SNAPSHOT

12.2.2 REVENUE ANALYSIS

12.2.3 COMPANY SHARE ANALYSIS

12.2.4 SWOT ANALYSIS

12.2.5 PRODUCT PORTFOLIO

12.2.6 RECENT DEVELOPMENT

12.3 THERMO FISHER SCIENTIFIC INC.

12.3.1 COMPANY SNAPSHOT

12.3.2 REVENUE ANALYSIS

12.3.3 COMPANY SHARE ANALYSIS

12.3.4 SWOT ANALYSIS

12.3.5 PRODUCT PORTFOLIO

12.3.6 RECENT DEVELOPMENTS

12.4 QIAGEN

12.4.1 COMPANY SNAPSHOT

12.4.2 REVENUE ANALYSIS

12.4.3 COMPANY SHARE ANALYSIS

12.4.4 SWOT ANALYSIS

12.4.5 PRODUCT PORTFOLIO

12.4.6 RECENT DEVELOPMENTS

12.5 AGILENT TECHNOLOGIES, INC.

12.5.1 COMPANY SNAPSHOT

12.5.2 REVENUE ANALYSIS

12.5.3 COMPANY SHARE ANALYSIS

12.5.4 SWOT ANALYSIS

12.5.5 PRODUCT PORTFOLIO

12.5.6 RECENT DEVELOPMENT

12.6 OXFORD NANOPORE TECHNOLOGIES

12.6.1 COMPANY SNAPSHOT

12.6.2 PRODUCT PORTFOLIO

12.6.3 RECENT DEVELOPMENTS

12.7 BIO-RAD LABORATORIES, INC.

12.7.1 COMPANY SNAPSHOT

12.7.2 REVENUE ANALYSIS

12.7.3 PRODUCT PORTFOLIO

12.7.4 RECENT DEVELOPMENTS

12.8X GENOMICS

12.8.1 COMPANY SNAPSHOT

12.8.2 REVENUE ANALYSIS

12.8.3 PRODUCT PORTFOLIO

12.8.4 RECENT DEVELOPMENTS

12.9 BIOMÉRIEUX SA

12.9.1 COMPANY SNAPSHOT

12.9.2 REVENUE ANALYSIS

12.9.3 PRODUCT PORTFOLIO

12.9.4 RECENT DEVELOPMENT

12.1 DNASTAR

12.10.1 COMPANY SNAPSHOT

12.10.2 PRODUCT PORTFOLIO

12.10.3 RECENT DEVELOPMENT

12.11 GENEIOUS

12.11.1 COMPANY SNAPSHOT

12.11.2 PRODUCT PORTFOLIO

12.11.3 RECENT DEVELOPMENTS

12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES

12.12.1 COMPANY SNAPSHOT

12.12.2 REVENUE ANALYSIS

12.12.3 PRODUCT PORTFOLIO

12.12.4 RECENT DEVELOPMENTS

12.13 HAMILTON COMPANY

12.13.1 COMPANY SNAPSHOT

12.13.2 PRODUCT PORTFOLIO

12.13.3 RECENT DEVELOPMENT

12.14 MACROGEN, INC.

12.14.1 COMPANY SNAPSHOT

12.14.2 REVENUE ANALYSIS

12.14.3 PRODUCT PORTFOLIO

12.14.4 RECENT DEVELOPMENT

12.15 NEW ENGLAND BIOLABS

12.15.1 COMPANY SNAPSHOT

12.15.2 PRODUCT PORTFOLIO

12.15.3 RECENT DEVELOPMENT

12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

12.16.1 COMPANY SNAPSHOT

12.16.2 REVENUE ANALYSIS

12.16.3 PRODUCT PORTFOLIO

12.16.4 RECENT DEVELOPMENTS

12.17 PARTEK, INCORPORATED

12.17.1 COMPANY SNAPSHOT

12.17.2 PRODUCT PORTFOLIO

12.17.3 RECENT DEVELOPMENT

12.18 PERKIN ELMER INC. (2021)

12.18.1 COMPANY SNAPSHOT

12.18.2 REVENUE ANALYSIS

12.18.3 PRODUCT PORTFOLIO

12.18.4 RECENT DEVELOPMENTS

12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

12.19.1 COMPANY SNAPSHOT

12.19.2 REVENUE ANALYSIS (PARENT COMPANY)

12.19.3 PRODUCT PORTFOLIO

12.19.4 RECENT DEVELOPMENTS

12.2 TAKARA BIO INC.

12.20.1 COMPANY SNAPSHOT

12.20.2 REVENUE ANALYSIS

12.20.3 PRODUCT PORTFOLIO

12.20.4 RECENT DEVELOPMENTS

13 QUESTIONNAIRE

14 RELATED REPORTS

List of Table

TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE

TABLE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 26 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 27 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 28 SOUTH AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 29 SOUTH AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 30 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 REST OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET

FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING

FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT

FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.

FIGURE 17 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021

FIGURE 18 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021

FIGURE 22 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021

FIGURE 26 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 28 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)

FIGURE 30 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)

FIGURE 31 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 32 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 33 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)

FIGURE 34 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET

FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING

FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT

FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.

FIGURE 17 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021

FIGURE 18 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021

FIGURE 22 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021

FIGURE 26 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 28 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)

FIGURE 30 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)

FIGURE 31 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 32 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 33 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)

FIGURE 34 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19